Vitrolife — Regulatory Filings 2012

Apr 12, 2012

Press release April 12, 2012 Gothenburg, Sweden

Conference call interim report

Invitation to attend Vitrolife's conference call regarding presentation of the interim report for the period January-March 2012. The presentation will be held in English.

Time: Friday, April 20, 2012 at 10 a.m. CET.

Registration can preferably be done in advance under the following link: https://eventreg1.conferencing.com/webportal3/reg.html?Acc=533433&Conf=183317

or shortly before the conference starts on: Sweden dial in number: +46 (0)8 505 201 10 UK dial in number: +44 (0)20 7162 0077 Conference name: Vitrolife, conference ID: 915308

Vitrolife participants: Thomas Axelsson, CEO Mikael Engblom, CFO

The press release for Vitrolife's interim report will be released at 3 p.m. CET on Thursday, April 19.

Before the conference call, slides will be available at the company web page, www.vitrolife.com/en/Corporate/.

A recorded version of the conference call will be available for seven days on number +46 (0)8 505 203 33 (Sweden) or +44 (0)20 7031 4064 (UK), access code 915308.

______________________________________________________________________________________________________________________

Gothenburg, April 12, 2012 VITROLIFE AB (publ)

Contact:

Mikael Engblom, CFO, phone +46 (0)31 721 80 14

Vitrolife is a global biotechnology/medical device Group that has business activities within the areas of fertility and transplantation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. There is also business to enable the use and handling of stem cells for therapeutic purposes. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keep them in optimal condition while waiting for transplantation.

Vitrolife today has approximately 220 employees and its products are sold in almost 90 markets. The company is headquartered in Gothenburg, Sweden, and there are offices in USA, Australia, France, Italy, United Kingdom, China and Japan. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap. ___________________________________________________________________________________________________________________________________________________________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 90. E-mail: info@vitrolife.com. Website: www.vitrolife.com

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.